En 2023, le prix net médian des cellules CAR-T industrielles en France a été estimé entre 212 550 et 220 110 €. Cette estimation, fondée sur les données publiques disponibles, permet de produire des hypothèses et ainsi mieux cerner le prix réel effectivement supporté par le système de santé tout en révélant l’opacité des mécanismes de tarification. La fixation des prix des cellules CAR-T repose sur un équilibre permanent entre valorisation de l’innovation, soutenabilité budgétaire et équité d’accès aux soins. À mesure que de nouvelles thérapies innovantes apparaissent et que leurs indications s’étendent, il devient indispensable de développer des évaluations médicoéconomiques complètes et transparentes ainsi que des outils de suivi performants en vie réelle tels que le registre DESCAR-T, afin d’orienter les décisions publiques et de garantir un accès équitable à ces innovations thérapeutiques majeures.

Current “ex vivo” CAR-T therapies are bespoke and labor-intensive. They require a personalized manufacturing slot for every single patient, leading to bottlenecks that leave desperate patients waiting weeks or months.
Vyriad’s approach, known as in vivo CAR-T, uses a modified lentivirus (LV-169) to act as a delivery truck.

• The Mechanism: The virus is engineered to seek out and bind specifically to T-cells inside the body
• The Payload: Once attached, it delivers a genetic instruction manual that teaches the T-cell to spot B-cell maturation antigen (BCMA), a protein found on multiple myeloma cancer cells
• The Result: The patient’s body becomes its own manufacturing facility, generating killer cells within days rather than weeks.

Mark Cuban warned that many employers are collecting drug rebate money funded by their sick employees — a practice that can violate fiduciary duties under ERISA. His company, Cost Plus Drugs, is partnering with organizations like Humana’s CenterWell to create direct-to-employer programs that bypass PBMs and deliver medications at lower net prices.

Columbia, Maryland-based Auxira Health was co-developed by healthcare provider MedStar Health and investment firm Abundant Venture Partners. The startup partners with cardiology practices and health systems and embeds virtual teams of advanced practice practitioners, medical assistants and registered nurses as an extension of the in-person care team. Each team member trains in-person with the physicians before they are transitioned into virtual care.

We've automated everything but the one workflow that most directly determines whether patients actually get the care they need. The gap between knowing what works and implementing it at scale reveals the real problem that healthcare treats referrals as an administrative burden to manage, not a critical workflow to optimize.

The American Heart Association is backing an AI startup aimed at improving detection of hard-to-diagnose conditions like cardiac amyloidosis and heart failure with preserved ejection fraction (HFpEF). The company, named Ultromics, offers a platform that analyzes routine echocardiograms to help clinicians catch disease earlier, particularly for women who are more likely to be missed.

Affordability, drug costs and AI will be top of mind for employers in 2026, according to Morgan Health CEO Dan Mendelson.

Des chercheurs ont développé une thérapie CAR-T à base de cellules tueuses naturelles (« natural killer », NK), qui s’est montrée plus efficace que les immunothérapies actuelles contre le cancer du sein triple négatif à un stade avancé – la forme la plus agressive de cancer du sein. La thérapie peut être produite en masse à partir de dons de cellules souches sanguines, ce qui réduirait considérablement son coût de développement. Sa polyvalence permettrait aussi de l’utiliser contre d’autres types de tumeurs solides.

Airiver received investigational device exemption approval from the US FDA to begin a pivotal clinical trial of the Airiver ESSpand Sinus Drug Coated Balloon in patients with chronic rhinosinusitis.

Women with heavy menstrual bleeding wait five years on average for care. Wyss technology could change that.

Electrospinning is a highly valuable technique known for its simplicity and versatility in producing 1D nanofibers, 2D nanofiber membranes, and highly porous 3D fiber structures. It can be combined with other methods to create biomimetic scaffolds, offering a wide range of possibilities in biomedical applications, drug delivery, and regenerative medicine. This technique utilizes both natural and synthetic polymers, as well as nanostructuring and scaffold properties, to achieve the desired outcomes.

One of the prevalent theories regarding the development of ICANS postulates that the rapid proliferation of CAR T cells leads to a robust inflammatory response, releasing a cascade of cytokines that may impact the central nervous system. High levels of these cytokines can penetrate the blood-brain barrier, leading to neuroinflammation and subsequent neurological symptoms. This cytokine release syndrome (CRS) often accompanies ICANS, further complicating the clinical picture.

A bipartisan Senate bill would boost transparency and oversight of pharmacy benefit managers by changing how they’re paid, expanding reporting requirements and strengthening protections for pharmacies and taxpayers.

Veradigm Senior Manager of Provider Performance and Tech Utilization Amanda Banister shared insights on how payers can lead the next phase of VBC implementation and how they can collaborate with providers more effectively.

Codoxo's funding was led by CVS Health Ventures and included participation from Echo Health Ventures, Sands Capital and 111 West Capital.

The leaders who will thrive are those who can see both sides of every equation: mission and margin, empathy and efficiency, innovation and trust. They’re the ones building organizations that don’t just survive policy shifts and economic pressure, but use them as catalysts for progress.

Beyond weight reduction and long-term maintenance of weight loss, the FDA decision for oral Wegovy covers use of the once-daily pill for reducing the risk of major cardiovascular events. Novo Nordisk expects the Wegovy tablet will launch in early January.

Avec 12 000 décès annuels en France, le cancer du sein reste la tumeur la plus meurtrière chez la femme. Les tests de séquençage génomique permettent désormais d’éviter une chimiothérapie inutile à de nombreuses patientes. Pourtant, leur remboursement incomplet freine leur usage, créant des inégalités d’accès aux soins.

Airway stenosis represents the most common airway complication following lung transplantation, affecting between 7% and 18% of patients. Idiopathic subglottic stenosis is a rare condition, mostly affecting women, with an estimated incidence of 1 in 400,000 people. There are ~100,000 tracheo-bronchial stenting and dilation procedures performed annually within the United States.

Chaque automne, Octobre Rose remet sur le devant de la scène la lutte contre le cancer du sein. Mais derrière la noble cause, certaines marques surfent sur la vague rose pour booster leurs ventes. L’UFC-Que Choisir dénonce cette année encore une multiplication d’opérations commerciales douteuses, où le symbole de solidarité devient un argument marketing.

MediView’s FDA-cleared surgical navigation and imaging platform empowers clinicians with “X-ray vision”—the ability to see a patient’s internal anatomy through their skin in full 3D context, overlaid directly onto their body. This technology simplifies procedures and expands access to less invasive care.
Current medical imaging systems force physicians to translate 2D images into 3D mental maps, creating a cognitive burden and disrupting natural hand-eye coordination. MediView replaces this limitation by fusing 3D CT scans with live ultrasound, enabling real-time, interactive visualization of organs, tissue, vasculature, and target anatomy like tumors.

Un dispositif d’aspiration de l’épiderme accroît sa perméabilité et entraîne une production d’anticorps plus efficace que lors d’une injection sous-cutanée.

Despite promising results from existing randomized controlled trials of semaglutide and tirzepatide in those with obesity-related HFpEF, regulatory authorities and professional societies have not approved or endorsed the use of these drugs for HFpEF, due in part to the studies’ relatively small sample sizes and unknown generalizability. The researchers therefore used data from three large U.S. insurance claims databases to emulate two previous, placebo-controlled trials of semaglutide and tirzepatide in new study populations that were an average of 19 times larger than those previously evaluated.